For many people with knee osteoarthritis, weight loss is the single most evidence-backed treatment available, and 2025 and 2026 brought the strongest proof yet. The STEP 9 trial found that people with obesity and knee osteoarthritis who took once-weekly semaglutide lost about 13.7% of their body weight and reported significantly less knee pain and better physical function than the placebo group. This article explains what the newest weight-loss research shows, how much weight loss actually matters, and how regenerative injections fit into the same plan.
13.7%
average weight loss with once-weekly semaglutide in STEP 9, versus 3.2% with placebo
10%
weight-loss threshold that reliably improves knee pain, function, and quality of life
~4 lb
of force across the knee removed for every pound of weight lost
STEP 9, published in the New England Journal of Medicine, randomized 407 adults with obesity and moderate knee osteoarthritis to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. The drug group lost 13.7% of body weight on average versus 3.2% for placebo, and reported a significantly larger reduction in knee pain on the WOMAC scale (minus 41.7 points versus minus 27.5) along with better physical function. It is, by a wide margin, the strongest single trial connecting intentional weight loss to knee pain relief, and it is why GLP-1 medications now appear in the osteoarthritis conversation.
“In STEP 9, adults with obesity and knee osteoarthritis who took once-weekly semaglutide lost 13.7% of body weight (versus 3.2% with placebo) and reported significantly less knee pain and better physical function.”
The well-established threshold is about 10% of starting body weight, where knee pain, function, and quality of life reliably improve. The research also shows a dose response: losing 10% to 20% works better than losing about 5%, and people who lose 20% or more report about 25% less pain than those who stop at 10%. Mechanically, every pound lost removes roughly four pounds of force across the knee during activity, which is why guideline after guideline places weight management at the core of knee osteoarthritis care.
The honest nuance: GLP-1 drugs are used off-label for osteoarthritis, results are not uniform across agents (one liraglutide trial showed no pain benefit despite meaningful weight loss), and a 2026 British Journal of Sports Medicine scoping review concludes they are a promising adjunct best integrated into supervised, multimodal musculoskeletal care. In other words, the evidence does not support swapping exercise, physical therapy, and load management for a prescription. It supports doing both.
This matters for anyone considering PRP or stem cell therapy for knee osteoarthritis, because weight and activity are the load foundation that injections build on. The 2026 evidence on PRP and cell therapy is real but modest, and exercise combined with injections appears to outperform injections alone. A thoughtful plan often looks like this: address weight and activity first, add guided exercise and physical therapy, then consider whether a regenerative injection adds enough on top of that foundation to be worth it for your specific knee.
A note from the clinic
At Aloha Stem Cell in Honolulu we treat the whole picture, not just the joint. That means honest conversations about weight, activity, and load before we ever talk injections, so the treatments you choose build on the strongest evidence available. Call (808) 593-2525 or book a consultation to start that conversation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.